ChristNeuroServo is announcing encouraging preliminary results from a clinical trial at the Centre hospitalier de l’Université de Montréal (CHUM) for post-operative delirium early detection.
After being granted investigational testing authorization (ITA) from Health Canada, NeuroServo, an early-stage medical device company developing an advanced portable and wireless prefrontal EEG is announcing encouraging preliminary results from a clinical trial at the Centre hospitalier de l’Université de Montréal (CHUM) for post-operative delirium early detection.
"Our technology not only captures the patient brainwaves with unprecedented accuracy, it also analyzes them in real time with our algorithms to identify pathology signatures such as post-operative delirium. Preliminary analysis of the data is extremely encouraging, we pursue our efforts on sensibility and specificity of our diagnostic aid device," said Nicolas Tremblay, President of NeuroServo.
Delirium is a condition affecting 10 to 31% of hospitalized patients aged 65 and over, dangerous for the patient and very expensive for the health system when diagnosed late. “Delirium is a common pathology with older patients causing longer hospital stay, cognitive decline and mortality. We target offering better medical care by improving delirium detection.” adds Patrick Nguyen, lead investigator, neuroscience researcher specialized in aging and delirium at CHUM Research Center.
Complete results will be published at the end of the clinical investigation mid 2022.
NeuroServo is an early stage medical device company developing an advanced portable and wireless prefrontal EEG with real-time brainwave analysis and pathology detection.
Earlier this year, NeuroServo received the highest medical device safety and performance certifications for VEEGix, its EEG.
NeuroServo is the recipient of the 2020 "Innovateurs(trices) en résidence" program, an 18 months comprehensive program structured to bring innovation to life.
NeuroServo is also accelerated by the 3Dexperience lab, a new laboratory to nurture and empower disruptive projects, and is supported by CTS Santé, Desjardins Capital, TransMedTech Institute, the Pole of Innovation and AI at the CHUM, PME MTL and CENTECH.
More about NeuroServo: https://www.neuroservo.com
Keywords : MedTech, medical device, startup, neuroscience, EEG, delirium
Company Name: NeuroServo Inc.
Contact Person: Jérôme Arnaud
Phone: +1 514.536.0250
Address: Montréal, Canada